Carbamazepine is FDA indicated for epilepsy, trigeminalÂ neuralgia, and acute manic and mixed episodes in bipolar I disorder.

Carbamazepine is used off-label for refractory schizophrenia. Simple well designed trials have shown efficacy in patients with schizophrenia with EEG abnormalities, schizophrenia with violent episodes, and schizoaffective disorder. It improves both positive and negative symptoms in schizophrenic patients.